U.S. Markets closed

OncoSec President and CEO Publishes New Blog Entitled “PD-1 and OncoSec’s Combination Study”

OncoSec Medical Inc. (OTCQB:ONCS), published a new blog post on The Chairman's Blog, written by the company's President and CEO, Punit Dhillon. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In the post Mr. Dhillon writes about the vision behind the company's sponsored research agreement with Old Dominion University and the Frank Reidy Research Center for Bioelectrics to initiate a combination study for the development of a new cancer treatment. He writes that, in the combination study, the company sees an "opportunity to increase response rates and overall effectiveness [of treatment]." Read the full blog post from Punit Dhillon on TheChairmansBlog.com (http://www.thechairmansblog.com/punit-dhillon/2013-10/pd-1-and-oncosecs-combination-study.html).

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors. ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietary use of an electroporation platform to enhance the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treatment of various solid cancers using these targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while potentially sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available at http://www.oncosec.com/.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publically and privatively held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. In addition to management`s insightful blog posts, TheChairmansBlog.com staff and aggregate partners contribute articles on finance, technology, health, and energy while providing updated market trends, news, and information.